Semi-mechanistic pharmacokinetic-pharmacodynamic modelling of antibiotic drug combinations.

BACKGROUND Deriving suitable dosing regimens for antibiotic combination therapy poses several challenges as the drug interaction can be highly complex, the traditional pharmacokinetic-pharmacodynamic (PKPD) index methodology cannot be applied straightforwardly, and exploring all possible dose combinations is unfeasible. Therefore, semi-mechanistic PKPD models developed based on in vitro single and combination experiments can be valuable to suggest suitable combination dosing regimens. AIMS To outline how the interaction between two antibiotics has been characterized in semi-mechanistic PKPD models. We also explain how such models can be applied to support dosing regimens and design future studies. SOURCES PubMed search for published semi-mechanistic PKPD models of antibiotic drug combinations. CONTENT Thirteen publications were identified where ten had applied subpopulation synergy to characterize the combined effect, i.e. independent killing rates for each drug and bacterial subpopulation. We report the various types of interaction functions that have been used to describe the combined drug effects and that characterized potential deviations from additivity under the PKPD model. Simulations from the models had commonly been performed to compare single versus combined dosing regimens and/or to propose improved dosing regimens. IMPLICATIONS Semi-mechanistic PKPD models allow for integration of knowledge on the interaction between antibiotics for various PK and PD profiles, and can account for associated variability within the population as well as parameter uncertainty. Decisions on suitable combination regimens can thereby be facilitated. We find the application of semi-mechanistic PKPD models to be essential for efficient development of antibiotic combination regimens that optimize bacterial killing and/or suppress resistance development.

[1]  France Mentré,et al.  Are Population Pharmacokinetic and/ or Pharmacodynamic Models Adequately Evaluated? , 2007, Clinical pharmacokinetics.

[2]  B. Meibohm,et al.  Translational PK/PD of anti-infective therapeutics. , 2016, Drug discovery today. Technologies.

[3]  D. Mager,et al.  Systems Pharmacology and Pharmacodynamics , 2016, AAPS Advances in the Pharmaceutical Sciences Series.

[4]  G. Drusano Pharmacokinetics and pharmacodynamics of antimicrobials. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[5]  M. Neely,et al.  Relevance of pharmacokinetic and pharmacodynamic modeling to clinical care of critically ill patients. , 2011, Current pharmaceutical biotechnology.

[6]  Pranita D. Tamma,et al.  Combination Therapy for Treatment of Infections with Gram-Negative Bacteria , 2012, Clinical Microbiology Reviews.

[7]  D. Eleveld,et al.  What about confidence intervals? A word of caution when interpreting PTA simulations. , 2016, The Journal of antimicrobial chemotherapy.

[8]  W. Huisinga,et al.  Translational Pharmacometric Evaluation of Typical Antibiotic Broad‐Spectrum Combination Therapies Against Staphylococcus Aureus Exploiting In Vitro Information , 2017, CPT: pharmacometrics & systems pharmacology.

[9]  Ulrika S. H. Simonsson,et al.  A general pharmacodynamic interaction model identifies perpetrators and victims in drug interactions , 2017, Nature Communications.

[10]  S. Wicha,et al.  Assessing Pharmacodynamic Interactions in Mice Using the Multistate Tuberculosis Pharmacometric and General Pharmacodynamic Interaction Models , 2017, CPT: pharmacometrics & systems pharmacology.

[11]  C. Landersdorfer,et al.  Aminoglycoside Concentrations Required for Synergy with Carbapenems against Pseudomonas aeruginosa Determined via Mechanistic Studies and Modeling , 2017, Antimicrobial Agents and Chemotherapy.

[12]  W. Greco,et al.  The search for synergy: a critical review from a response surface perspective. , 1995, Pharmacological reviews.

[13]  H. Derendorf,et al.  Evaluation of in vitro synergy between vertilmicin and ceftazidime against Pseudomonas aeruginosa using a semi-mechanistic pharmacokinetic/pharmacodynamic model. , 2015, International journal of antimicrobial agents.

[14]  C. I. Bliss THE TOXICITY OF POISONS APPLIED JOINTLY1 , 1939 .

[15]  A. Schumitzky,et al.  Analysis of Combination Drug Therapy to Develop Regimens with Shortened Duration of Treatment for Tuberculosis , 2014, PloS one.

[16]  O. Cars,et al.  Dynamic interaction of colistin and meropenem on a WT and a resistant strain of Pseudomonas aeruginosa as quantified in a PK/PD model. , 2016, The Journal of antimicrobial chemotherapy.

[17]  H. Derendorf,et al.  Pharmacokinetics and pharmacodynamics in antibiotic dose optimization , 2016, Expert opinion on drug metabolism & toxicology.

[18]  M. Karlsson,et al.  A whole-body physiologically based pharmacokinetic (WB-PBPK) model of ciprofloxacin: a step towards predicting bacterial killing at sites of infection , 2016, Journal of Pharmacokinetics and Pharmacodynamics.

[19]  A. Kristoffersson Study Design and Dose Regimen Evaluation of Antibiotics based on Pharmacokinetic and Pharmacodynamic Modelling , 2015 .

[20]  Mickael Guedj,et al.  Analysis of drug combinations: current methodological landscape , 2015, Pharmacology research & perspectives.

[21]  THT Nguyen,et al.  Model Evaluation of Continuous Data Pharmacometric Models: Metrics and Graphics , 2017, CPT: pharmacometrics & systems pharmacology.

[22]  Neang S. Ly,et al.  Polymyxin B in combination with doripenem against heteroresistant Acinetobacter baumannii: pharmacodynamics of new dosing strategies. , 2016, The Journal of antimicrobial chemotherapy.

[23]  Neang S. Ly,et al.  Optimization of Polymyxin B in Combination with Doripenem To Combat Mutator Pseudomonas aeruginosa , 2016, Antimicrobial Agents and Chemotherapy.

[24]  Lena E. Friberg,et al.  Pharmacokinetic/Pharmacodynamic (PK/PD) Indices of Antibiotics Predicted by a Semimechanistic PKPD Model: a Step toward Model-Based Dose Optimization , 2011, Antimicrobial Agents and Chemotherapy.

[25]  H. Derendorf,et al.  Experimental design and modelling approach to evaluate efficacy of β-lactam/β-lactamase inhibitor combinations. , 2017, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[26]  Neang S. Ly,et al.  Colistin and doripenem combinations against Pseudomonas aeruginosa: profiling the time course of synergistic killing and prevention of resistance. , 2015, The Journal of antimicrobial chemotherapy.

[27]  C. Landersdorfer,et al.  High-intensity meropenem combinations with polymyxin B: new strategies to overcome carbapenem resistance in Acinetobacter baumannii , 2017, The Journal of antimicrobial chemotherapy.

[28]  C. Landersdorfer,et al.  Novel Approach To Optimize Synergistic Carbapenem-Aminoglycoside Combinations against Carbapenem-Resistant Acinetobacter baumannii , 2015, Antimicrobial Agents and Chemotherapy.

[29]  C. Landersdorfer,et al.  Optimization of Synergistic Combination Regimens against Carbapenem- and Aminoglycoside-Resistant Clinical Pseudomonas aeruginosa Isolates via Mechanism-Based Pharmacokinetic/Pharmacodynamic Modeling , 2016, Antimicrobial Agents and Chemotherapy.

[30]  H. Derendorf,et al.  Prediction of in vivo and in vitro infection model results using a semimechanistic model of avibactam and aztreonam combination against multidrug resistant organisms , 2017, CPT: pharmacometrics & systems pharmacology.

[31]  Neang S. Ly,et al.  Quantifying Subpopulation Synergy for Antibiotic Combinations via Mechanism-Based Modeling and a Sequential Dosing Design , 2013, Antimicrobial Agents and Chemotherapy.

[32]  Lena E Friberg,et al.  Pharmacokinetic-Pharmacodynamic Modeling of Antibacterial Drugs , 2013, Pharmacological Reviews.